CN104271581B - 用作电压门控钠通道调制剂的2-(吡啶-2基)-1,7-二氮杂螺[4.4]壬-6-酮化合物 - Google Patents
用作电压门控钠通道调制剂的2-(吡啶-2基)-1,7-二氮杂螺[4.4]壬-6-酮化合物 Download PDFInfo
- Publication number
- CN104271581B CN104271581B CN201280070485.0A CN201280070485A CN104271581B CN 104271581 B CN104271581 B CN 104271581B CN 201280070485 A CN201280070485 A CN 201280070485A CN 104271581 B CN104271581 B CN 104271581B
- Authority
- CN
- China
- Prior art keywords
- compound
- acid
- formula
- methyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC*(C)C(C1C(CC)CCC1)=O Chemical compound CC*(C)C(C1C(CC)CCC1)=O 0.000 description 1
- HBROCCNQEGMCNN-DGMLTAMKSA-N CC/C=C(\C=C/N)/c1cc(OC(F)(F)F)ccc1 Chemical compound CC/C=C(\C=C/N)/c1cc(OC(F)(F)F)ccc1 HBROCCNQEGMCNN-DGMLTAMKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579613P | 2011-12-22 | 2011-12-22 | |
| US61/579,613 | 2011-12-22 | ||
| GB1122113.2 | 2011-12-22 | ||
| US61/579613 | 2011-12-22 | ||
| GBGB1122113.2A GB201122113D0 (en) | 2011-12-22 | 2011-12-22 | Novel compounds |
| PCT/GB2012/053233 WO2013093496A1 (en) | 2011-12-22 | 2012-12-21 | 2 - (pyridin- 2yl) - 1, 7 -diaza-spiro [4.4] nonane- 6 -one compound as voltage-gated sodium channels modulator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104271581A CN104271581A (zh) | 2015-01-07 |
| CN104271581B true CN104271581B (zh) | 2016-08-31 |
Family
ID=45572877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280070485.0A Expired - Fee Related CN104271581B (zh) | 2011-12-22 | 2012-12-21 | 用作电压门控钠通道调制剂的2-(吡啶-2基)-1,7-二氮杂螺[4.4]壬-6-酮化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9303032B2 (https=) |
| EP (2) | EP2797922B1 (https=) |
| JP (2) | JP2015502394A (https=) |
| KR (1) | KR20140113692A (https=) |
| CN (1) | CN104271581B (https=) |
| AU (1) | AU2012356386A1 (https=) |
| BR (1) | BR112014014940A2 (https=) |
| CA (1) | CA2858938C (https=) |
| EA (1) | EA026500B1 (https=) |
| ES (1) | ES2581327T3 (https=) |
| GB (1) | GB201122113D0 (https=) |
| HK (2) | HK1203501A1 (https=) |
| IL (1) | IL233215A0 (https=) |
| IN (1) | IN2014MN01469A (https=) |
| MX (1) | MX2014007637A (https=) |
| SG (1) | SG11201403356YA (https=) |
| WO (2) | WO2013093497A1 (https=) |
| ZA (1) | ZA201404269B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) * | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| RU2650523C1 (ru) * | 2017-07-24 | 2018-04-16 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Производное пиридоксина для лечения эпилепсии |
| CA3077088A1 (en) | 2017-10-10 | 2019-04-18 | Biogen Inc. | Process for preparing spiro derivatives |
| CA3081553C (en) | 2017-11-17 | 2022-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of eye disorders |
| CN113563258A (zh) * | 2021-07-29 | 2021-10-29 | 派普医药(江苏)有限公司 | 一种4-溴-2-(二氟甲基)-5-甲基吡啶的制备方法 |
| WO2023044364A1 (en) | 2021-09-15 | 2023-03-23 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
| EP4405344A2 (en) * | 2021-09-24 | 2024-07-31 | Xenon Pharmaceuticals Inc. | Pyridinyl derivatives as sodium channel activators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898239A (zh) * | 2003-10-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途 |
| WO2008090115A1 (en) * | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
| CN101326162A (zh) * | 2005-10-10 | 2008-12-17 | 葛兰素集团有限公司 | 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| ES2183935T3 (es) | 1995-02-13 | 2003-04-01 | Searle & Co | Isoxazoles sustituidos para el tratamiento de la inflamacion. |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| SK285353B6 (sk) | 1996-04-12 | 2006-11-03 | G. D. Searle & Co. | Substituované benzénsulfónamidy ako proliečivá COX-2 inhibítorov, farmaceutická kompozícia a spôsobich prípravy a použitia |
| IL127441A (en) | 1996-07-18 | 2003-02-12 | Merck Frosst Canada Inc | Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| ES2256817T3 (es) | 1997-09-05 | 2006-07-16 | Glaxo Group Limited | Composiciones farmaceuticas que comprenden derivados de 2,3-diaril-pirazolo(1,5-b)piridazina. |
| HUP0104204A3 (en) | 1998-11-03 | 2002-06-28 | Glaxo Group Ltd | Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| US6498166B1 (en) | 1999-02-27 | 2002-12-24 | Smithkline Beecham Corporation | Pyrazolopyridines |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0323204D0 (en) | 2003-10-03 | 2003-11-05 | Novartis Ag | Organic compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| US7505330B2 (en) * | 2006-08-31 | 2009-03-17 | Micron Technology, Inc. | Phase-change random access memory employing read before write for resistance stabilization |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0706630D0 (en) | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| JP5855000B2 (ja) | 2009-09-14 | 2016-02-09 | クオンベルゲンセ プハルマセウトイカルス リミテッド | α−カルボキサミド誘導体の製造方法 |
| MX2012004373A (es) * | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
-
2011
- 2011-12-22 GB GBGB1122113.2A patent/GB201122113D0/en not_active Ceased
-
2012
- 2012-12-21 KR KR1020147019965A patent/KR20140113692A/ko not_active Withdrawn
- 2012-12-21 ES ES12810416.3T patent/ES2581327T3/es active Active
- 2012-12-21 WO PCT/GB2012/053234 patent/WO2013093497A1/en not_active Ceased
- 2012-12-21 JP JP2014548201A patent/JP2015502394A/ja active Pending
- 2012-12-21 CA CA2858938A patent/CA2858938C/en active Active
- 2012-12-21 BR BR112014014940A patent/BR112014014940A2/pt not_active Application Discontinuation
- 2012-12-21 US US14/365,391 patent/US9303032B2/en not_active Expired - Fee Related
- 2012-12-21 US US14/365,372 patent/US9376436B2/en not_active Expired - Fee Related
- 2012-12-21 EP EP12810416.3A patent/EP2797922B1/en not_active Not-in-force
- 2012-12-21 AU AU2012356386A patent/AU2012356386A1/en not_active Abandoned
- 2012-12-21 HK HK15104075.3A patent/HK1203501A1/xx unknown
- 2012-12-21 WO PCT/GB2012/053233 patent/WO2013093496A1/en not_active Ceased
- 2012-12-21 EA EA201491251A patent/EA026500B1/ru unknown
- 2012-12-21 EP EP12810417.1A patent/EP2794612B1/en not_active Not-in-force
- 2012-12-21 HK HK15103930.0A patent/HK1203492A1/xx unknown
- 2012-12-21 MX MX2014007637A patent/MX2014007637A/es unknown
- 2012-12-21 CN CN201280070485.0A patent/CN104271581B/zh not_active Expired - Fee Related
- 2012-12-21 IN IN1469MUN2014 patent/IN2014MN01469A/en unknown
- 2012-12-21 JP JP2014548202A patent/JP2015502395A/ja active Pending
- 2012-12-21 SG SG11201403356YA patent/SG11201403356YA/en unknown
-
2014
- 2014-06-10 ZA ZA2014/04269A patent/ZA201404269B/en unknown
- 2014-06-18 IL IL233215A patent/IL233215A0/en unknown
-
2016
- 2016-02-25 US US15/053,445 patent/US20160185758A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898239A (zh) * | 2003-10-23 | 2007-01-17 | 阿斯利康(瑞典)有限公司 | 新的二氮杂螺烷及其在治疗ccr8介导的疾病中的用途 |
| CN101326162A (zh) * | 2005-10-10 | 2008-12-17 | 葛兰素集团有限公司 | 作为电压门控钠通道的调控剂的季铵化的α-氨基甲酰胺衍生物 |
| WO2008090115A1 (en) * | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2797922A1 (en) | 2014-11-05 |
| GB201122113D0 (en) | 2012-02-01 |
| US20140350040A1 (en) | 2014-11-27 |
| WO2013093497A1 (en) | 2013-06-27 |
| SG11201403356YA (en) | 2014-07-30 |
| EP2797922B1 (en) | 2016-04-06 |
| JP2015502394A (ja) | 2015-01-22 |
| IN2014MN01469A (https=) | 2015-04-17 |
| IL233215A0 (en) | 2014-08-31 |
| CN104271581A (zh) | 2015-01-07 |
| CA2858938A1 (en) | 2013-06-27 |
| EA201491251A1 (ru) | 2014-11-28 |
| US9376436B2 (en) | 2016-06-28 |
| EP2794612B1 (en) | 2016-04-06 |
| US20150225400A1 (en) | 2015-08-13 |
| US9303032B2 (en) | 2016-04-05 |
| ES2581327T3 (es) | 2016-09-05 |
| MX2014007637A (es) | 2014-09-26 |
| EA026500B1 (ru) | 2017-04-28 |
| ZA201404269B (en) | 2016-06-29 |
| HK1203501A1 (en) | 2015-10-30 |
| JP2015502395A (ja) | 2015-01-22 |
| WO2013093496A1 (en) | 2013-06-27 |
| EP2794612A1 (en) | 2014-10-29 |
| KR20140113692A (ko) | 2014-09-24 |
| HK1203492A1 (en) | 2015-10-30 |
| BR112014014940A2 (pt) | 2017-06-13 |
| AU2012356386A1 (en) | 2014-07-10 |
| US20160185758A1 (en) | 2016-06-30 |
| CA2858938C (en) | 2020-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104271581B (zh) | 用作电压门控钠通道调制剂的2-(吡啶-2基)-1,7-二氮杂螺[4.4]壬-6-酮化合物 | |
| US10485801B2 (en) | Pyrimidinyl-diazospiro compounds | |
| HK1232519A1 (en) | Novel compounds | |
| HK1232519B (en) | Novel compounds | |
| HK1209423B (en) | 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160831 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |